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Research into bone marrow adiposity (BMA) has expanded greatly since the late 1990s,
leading to development of new methods for the study of bone marrow adipocytes.
Simultaneously, research fields interested in BMA have diversified substantially. This
increasing interest is revealing fundamental new knowledge of BMA; however, it has also
led to a highly variable nomenclature that makes it difficult to interpret and compare
results from different studies. A consensus on BMA nomenclature has therefore become
indispensable. This article addresses this critical need for standardised terminology and
consistent reporting of parameters related to BMA research. The International Bone
Marrow Adiposity Society (BMAS) was formed in 2017 to consolidate the growing
scientific community interested in BMA. To address the BMA nomenclature challenge,
BMAS members from diverse fields established a working group (WG). Based on their
broad expertise, the WG first reviewed the existing, unsystematic nomenclature and
identified terms, and concepts requiring further discussion. They thereby identified and
defined 8 broad concepts and methods central to BMA research. Notably, these had
been described using 519 unique combinations of term, abbreviation and unit, many
of which were overlapping or redundant. On this foundation a second consensus was
reached, with each term classified as “to use” or “not to use.” As a result, theWG reached
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a consensus to craft recommendations for 26 terms related to concepts and methods in
BMA research. This was approved by the Scientific Board and Executive Board of BMAS
and is the basis for the present recommendations for a formal BMA nomenclature. As
an example, several terms or abbreviations have been used to represent “bone marrow
adipocytes,” including BMAds, BM-As, and BMAs. The WG decided that BMA should
refer to “bone marrow adiposity”; that BM-A is too similar to BMA; and noted that “Ad”
has previously been recommended to refer to adipocytes. Thus, it was recommended
to use BMAds to represent bone marrow adipocytes. In conclusion, the standard
nomenclature proposed in this article should be followed for all communications of results
related to BMA. This will allow for better interactions both inside and outside of this
emerging scientific community.
Keywords: nomenclature, bone marrow adiposity, bone marrow adipose tissue, bone marrow adipocyte, skeletal
stem cells, histomorphometry, MRI, computed tomography
INTRODUCTION
Bone marrow adiposity (BMA) is the phenomenon of fat storage
within the bone marrow (BM). Several different cell types within
the skeleton are capable of lipid uptake, including haematopoietic
stem cells and osteoblasts (1–3). However, BM adipocytes are the
principal cell type responsible for this BM fat storage. Studies
relating to BMA have been published since at least the mid-
nineteenth century, yet for much of the twentieth century there
was relatively little research in this field. However, the past
20 years have seen a resurgence of interest in this topic: even
as publication rates have grown across all fields, publications
relating to BMA are increasing at an even greater rate (Figure 1).
While the earliest studies of BM adipocytes focused on their
roles in haematopoiesis, the field has since expanded to include
many other disciplines, including skeletal biology, endocrinology
and metabolism, stem cells, cancer biology, ageing, biomedical
imaging, and beyond. This multidisciplinary nature is one of
the strengths of the burgeoning BMA research community;
however, it has also contributed to increasing variability in
the terminology used in the BMA literature (Figure 1). This
is leading to confusion and risks hindering progress in this
field. Therefore, there is a need for a standardised nomenclature
to facilitate communication between researchers from different
fields, and to provide a foundation and consensus for future
research relating to BMA.
The challenges for BMA nomenclature were first discussed
in 2017 at the Third International Meeting on Bone Marrow
Adiposity in Lausanne, Switzerland (4). To address this challenge,
members of the International Bone Marrow Adiposity Society
(BMAS), representing diverse fields, established a Nomenclature
Working Group (WG). The authors of this manuscript represent
the Nomenclature WG of BMAS. Our WG has since met several
times, including via teleconference and in person, to identify
the present state of nomenclature relevant to BMA research and
to identify recommended terms, abbreviations and units for a
standardised nomenclature. As stated in a previous nomenclature
FIGURE 1 | Growth in publications and terminology related to bone marrow
adiposity. The number of publications and unique terms relevant to the study
of bone marrow adiposity (BMA) are shown, arranged by decade of
publication. Also shown is the total number of papers indexed in PubMed for
each time period. Publications relevant to BMA were identified through a
systematic search of PubMed using the following terms: “marrow[Title] AND
(fat[Title/Abstract] OR adipose[Title/Abstract] OR adipocyte[Title/Abstract] OR
adiposity[Title/Abstract])”; publication dates up to 31/07/2019 were included.
Because earlier studies (e.g., pre-1950) are often not indexed in PubMed,
many of these papers were added manually based on our existing knowledge
of the literature. Search results were then manually assessed to identify
publications relevant to the study of BMA and to exclude results that were not
directly relevant. This was necessary because many results related to other
subjects, such as fat embolisms of bone marrow or, from 2000 onwards,
adipose tissue stem cells. This approach identified 568 papers relevant to
BMA nomenclature. By reading these papers, we distinguished the full range
of terms that have been used to report concepts and/or measurements related
to BMA research. If terms were associated with an abbreviation and/or unit of
measurement, these were also recorded. Together, this generated a list of 519
unique combinations of term, abbreviation and unit; if two papers used the
same term (e.g., bone marrow adipocyte) but with different abbreviations or
units (e.g., BMAd vs. BM-AD), then these were counted as two unique terms.
The number of papers and unique terms used per decade are shown. Key
concepts and methods are described in Table 1, and terms related to these
are presented in Tables 2–9. Further details are provided in
Supplementary Tables 1–8.
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position paper for bone histomorphometry (5), “Our purpose is
not to encourage or discourage the use of abbreviations and symbols
but to ensure that the same ones are used by everybody.”
PUBLICATIONS AND TERMINOLOGY FOR
THE STUDY OF BONE MARROW
ADIPOSITY: HISTORICAL PERSPECTIVES
The existence of adipocytes as a major component of the BM
has been noted since at least the 1860s, when Bizozzero and
Neumann independently identified BM as the site of blood
production (6, 7). In his seminal 1875 book on histology, Ranvier
noted that caudal vertebrae of tailed animals are full of fat
(8), further confirming that fat is a constituent of normal BM
anatomy. Thereafter, references to fat cells, “yellow marrow”
and “yellow adipose tissue” within the BM can be found not
only in the writings of Neumann (9), but also in contemporary
English-language works on pathology and BM anatomy (10, 11).
Indeed, Coats noted that the BM is a place “where normally
adipose tissue exists” (10). Use of the term “yellow marrow”
underscored its distinction from the “red marrow” in which
haematopoiesis occurs.
Piney’s excellent 1922 paper summarised these earlier studies
of BM anatomy but used the term “fatty marrow” instead of
“yellow marrow” or “yellow adipose tissue” (12). Both “fatty
marrow,” “yellowmarrow,” and “yellow bone marrow” continued
to be used interchangeably in the 1930s, sometimes being
combined into the term “yellow fatty marrow” (13–19) or
“yellow fat” (15). These and other contemporaneous studies
continued to highlight the existence of “fat cells” in histological
BM sections (15, 16, 18–21) but the term “adipocyte” is rarely
used, and some papers ignore this cellular nature by instead
referring to “fat spaces,” (22). Still other studies mention BM
fat cells without referring to “fatty marrow” or “yellow marrow”
(20, 21), and vice versa (17). Thus, in the 1930s it seems
that BM adipocytes were not yet considered as an integrated
adipose tissue.
In the latter half of the 1930s and the early 1940s, the term
“bone marrow fat” begins to appear, often used alongside “fatty
marrow” and “yellow marrow” (19, 23). The term “red marrow
fat” was also used in contrast to “yellow marrow fat” (23); this
demonstrates recognition that adipocytes also exist in the red
marrow, and that these may have different properties to those
within the yellow marrow. Hilditch and Murti further noted that
the “bone marrow fat” of oxen shares properties of perinephric
adipose tissue (23), presaging later suggestions that adipocytes
within BM might constitute a bona fide adipose tissue (24).
Nevertheless, the notion of marrow fat as an adipose tissue was
not reiterated until the mid-1950s when Evans et al. suggested
that marrow fat is essentially a fat depot, based on its similar
lipid composition to perinephric adipose tissue (24). This period
also sees the first use of more-quantitative histomorphometric
analyses (25, 26), although it is not until the late 1980s that this
would become widespread.
From the mid-1950s to mid-1960s the use of “marrow fat”
became far more prevalent (24, 27–30), largely replacing “yellow
marrow” as the term of choice. One notable exception is the 1967
study by Zakaria and Shafrir (31), who introduced the acronym
“YBM” to refer to yellow bone marrow. They showed that, like
white adipose tissue (WAT), YBM is capable of uptake and
esterification of glucose and free fatty acids, as well as lipolysis for
fatty acid release. Based on this, they concluded that YBM could
be considered an adipose tissue. This period also includes one
of the earliest uses of “marrow adiposity” (32), a term that has
become increasingly prevalent in the past two decades (Table 2).
The 1970s saw increased interest in BMA, with notable growth
in both the number of publications and the range of terms
used therein (Figure 1). The terms “bone marrow adipose tissue”
and “bone marrow adipocyte” first appear in the mid-1970s
(33, 34), with another obvious shift being the increasing use of
“marrow adipose cells,” “marrow adipocytes,” “marrow adipose
tissue,” or “bone marrow adipose tissue” (33–45). This may
reflect the growing recognition of BM adipocytes, collectively,
as an integrated adipose tissue. However, many contemporary
papers continued using “fatty marrow,” “yellow marrow,” and
“marrow fat” (46–51), and in some cases a mixture of all of
these terms can be found within a single paper (52). Thus, the
increased study of BMA did not coincide with any consensus or
standardisation of the nomenclature used. The late 1970s also saw
the use of terms to specify anatomical location, such as “femoral”
or “vertebral adipose cell” (40), or “proximal” and “distal” to
describe marrow fat and red marrow (51). As we discuss herein
in the section on Subtypes of Bone Marrow Adipocytes, terms
addressing the site-specific properties of BM adipocytes are an
important aspect of the standardised nomenclature for BMA
research (Tables 1, 6).
The number of BMA-related publications and terms
continued to increase in the 1980s (Figure 1), with one
notable development being the emergence of new methods
for quantitative assessment of BMA. These include magnetic
resonance imaging (MRI) (53–57), computed tomography
(CT) and dual-energy CT (58–61), and advances in
histomorphometric analysis (62–64). Typically, these methods
provide readouts of the fraction of BM consisting of fat or
adipocytes, as reflected by use of terms such as “fat fraction” (56),
“fat content” (57–59, 61, 65), and “adipose tissue fraction” (63).
These method-related terms often are associated with units of
measurement, although the units used frequently vary between
studies. This theme has persisted in more-recent BMA research,
with numerous combinations of terms, abbreviations, and
units applied to the same measurement (Tables 7–9). Thus, an
important goal of our proposed nomenclature is to standardise
the terminology used in reporting common measurements in the
BMA field.
In the 1990s there was further growth in the number of terms
used, despite a slight decrease in publications (Figure 1). This
suggests an increasing diversity and continued lack of consensus
for BMA nomenclature. Studies using histomorphometry orMRI
became increasingly prevalent, with proton magnetic resonance
spectroscopy (1H-MRS) also emerging as a powerful tool for
BMA quantification (Tables 7, 8). The 1990s also saw an
increased focus on progenitors for BM adipocytes, exemplified
by references to “bone marrow stromal cells” (Table 6).
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TABLE 1 | Key concepts and methods in the field of bone marrow adiposity.
Concept or method Definition Recommended terms and abbreviations Further
details
Bone marrow
adiposity
The phenomenon of fat storage within the bone marrow
(BM), primarily within BM adipocytes.
• Bone marrow adiposity (BM adiposity; BMA)
• Yellow marrow; red marrow; fatty marrow (Not abbreviated)
Table 2
Bone marrow
adipocytes
The cells within the BM whose primary function is lipid
storage.
• Bone marrow adipocyte (BM adipocyte; BMAd) Table 3
Bone marrow
adipose tissue
The functionally integrated tissue formed collectively by
BM adipocytes
• Bone marrow adipose tissue (BMAT)
• Bone marrow fat (BM fat)
Table 4
Site-specific
differences (BMAd
subtypes)
The concept that BM adipocytes have distinct
morphological, molecular and functional characteristics,
depending on their skeletal location. This may also apply to
BMAd progenitors.
• Constitutive or Regulated BMAT or BMAd (cBMAT, cBMAd;
rBMAT, rBMAd)
• Use “distal” or “proximal” to denote BMAT or BMAd location
within long bones; and bone-specific terms to denote skeletal
site (e.g., femoral, tibial, vertebral, etc…)
Table 5
Stem and progenitor
cells
The self-renewing, multipotent progenitor cells within the
BM that give rise to adipocytes, osteoblasts,
chondrocytes, and fibroblasts.
• Skeletal stem cell (SSC)
• Bone marrow stromal cell (BMSC)
• Do not refer to bone marrow/mesenchymal “stem” cells (this
is a misnomer)
Table 6
Histo-morphometry Use of histomorphometry to quantify bone marrow
adiposity, either on a per-adipocyte level (e.g., Ad.Ar,
Ad.Dm, Ad.Pm)* or a whole-tissue level (e.g., adipocyte
density, adipose area, adipose volume).
• Adipocyte area (Ad.Ar, µm2 )
• Adipocyte diameter (Ad.Dm, µm)
• Adipocyte perimeter (Ad.Pm, µm)
• Adipocyte density or Adipocyte Number* (N.Ad relative to
Ma.Ar, Ma.V, T.Ar or TV)
• Adipose area* (Ad.Ar relative to Ma.Ar, T.Ar; report as %)
• Adipose volume* (Ad.V relative to Ma.V or TV; report as %)
Table 7
Magnetic resonance
imaging or
spectroscopy
(MRI/MRS)
Use of proton-based MRI/MRS to quantify the proportion
or absolute amount of fat within the BM. Typically in vivo,
volumetric measurements.
• Fat fraction (FF, %)
• Bone marrow fat fraction (BMFF, %)
• Proton density fat fraction (PDFF, %)
Table 8
Computed
tomography
Use of CT to estimate BM fat fraction, or µCT to measure
BMAT volume or BMAd density. Typically done ex vivo
using contrast agents but can also be done in vivo.
• FF (%) or BMFF (%)
• Adipose area per marrow area*(Ad.Ar/Ma.Ar, %)
• Adipose volume per marrow volume* (Ad.V/Ma.V, %)
• Adipocyte density* (N.Ad/Ma.V or N.Ad/M.Ar)
Table 9
These concepts and methods were identified through a systematic literature search, as described in the legend to Figure 1. The recommendations include 26 unique terms and 35
abbreviations. Abbreviations used in this table (*) are defined as follows: N.Ad, adipocyte number; Ad.Ar, total adipocyte area; Ad.V, total adipocyte volume; Ma.Ar, marrow area; Ma.V,
marrow volume; T.Ar, tissue area; TV, tissue volume. Further details for each concept/method are provided in the indicated tables and in the main text.
The numbers of BMA-related papers and terminology further
increased in the 2000s, and since 2010 this growth has been even
more substantial (Figure 1). The abbreviation BMAT, for “bone
marrow adipose tissue,” first appears in 2007 (66), preceding
the first use of MAT (“marrow adipose tissue”) in 2012 (67);
each of these abbreviations is now widespread in the BMA
literature (Table 3). Similarly, “bone marrow adiposity” first
appears in 2002 but has become increasingly prevalent ever
since (68) (Table 2). The past two decades have also witnessed
the development of new methods for BMA analysis, including
µCT of osmium tetroxide-stained bones (69, 70) and advances
in MRI/MRS-based quantitation (71). These developments
therefore have led to the introduction of additional new terms
related to such methods (Tables 7–9). Many other notable terms
have also emerged in the BMA literature during this period,
such as SSC (for “skeletal stem cell”) (72) (Table 6), and use
of “regulated” and “constitutive” to distinguish distinct BMAT
subtypes (73) (Table 5). Given the vast number of terms used
since 2000, it is not possible to succinctly summarise all of the
key developments in these paragraphs. Therefore, readers should
consult Tables 1–9, and further data in the Supplement, for a
full overview of the nomenclature used in the BMA literature
to date.
KEY CONCEPTS AND GOALS FOR A
STANDARDISED NOMENCLATURE
This historical overview is based on our systematic search of
PubMed (Figure 1) and our knowledge of other less-accessible
papers. Thus, references to the “first use” of a term apply only
to this extensive body of BMA-related literature; because some
relevant publications may have been missed, some terms may
have even earlier uses. Nevertheless, these historical perspectives
Frontiers in Endocrinology | www.frontiersin.org 4 January 2020 | Volume 10 | Article 923
Bravenboer et al. BMA Nomenclature
TABLE 2 | Summary of terms and abbreviations that have been used to refer to bone marrow adiposity, yellow marrow, fatty marrow, or red marrow.
Term Abbreviation Year first used* No. of papers using this term* Recommended term(s) and abbreviation(s)
BONE MARROW ADIPOSITY
Marrow adiposity – 1967 119 Bone marrow adiposity (BM adiposity, BMA)
Bone marrow adiposity – 2002 78
BM adiposity 2011 12
BMA 2013 9
BMAT 2017 1
Bone adiposity – 2009 4
YELLOW MARROW
Yellow marrow – 1883 109 Yellow marrow (No abbreviation)
YM 2010 1
Yellow bone marrow – 1936 23
YBM 1967 2
Yellow BM 1996 2
YM 2019 1
Yellow fatty marrow; yellow fatty bone
marrow; yellow fat marrow
– 1933 7
FATTY MARROW
Fatty marrow – 1922 82 Fatty marrow (No abbreviation)
Fatty bone marrow – 1990 7
Fatty BM 2008 1
Fatty yellow marrow – 2013 7
RED MARROW
Red marrow – 1883 122 Red marrow (No abbreviation)
RM 2010 2
Red marrow (active marrow) – 2003 1
Red bone marrow – 1922 21
Red BM 1996 2
RM 2019 1
RBM 2015 2
h(a)em(at)opoietic marrow – 1936 24
OTHER TERMS (SEE SUPPLEMENTARY TABLE 1)
Relevant terms and abbreviations were identified through a systematic search of the literature relating to bone marrow adiposity. Within these search results, the total number of papers
using each term/abbreviation combination is indicated, along with the year that these were first used; asterisks (*) are shown to emphasise that other uses may exist. For most terms,
no abbreviation is used (–). Based on this and other considerations (described in the main text), we recommend use of the term bone marrow adiposity (abbreviated as “BM adiposity”
or “BMA”). Use of the terms “yellow marrow,” “fatty marrow” or “red marrow” is also acceptable, given the long-term use of these terms in the BMA literature. Red marrow is in some
cases described as hematopoietic marrow, hemopoietic marrow, haematopoietic marrow or haemopoietic marrow; for simplicity, we have grouped together papers using these spelling
variants. Terms specific to measurements of bone marrow adiposity, such as “fat fraction” or “fat content,” have not been included and are shown instead in Tables 6–8. Additional
terms and abbreviations, as well as references for papers using each combination, are provided in Supplementary Table 1.
on the BMA literature provide an essential foundation on which
to establish a standardised nomenclature for studies relevant
to BMA. The two major benefits of this literature review are
as follows.
Firstly, we show that the existing BMA literature uses a
highly diverse, heterogeneous terminology to report concepts
and measurements relevant to BMA. As shown in Figure 1, the
rate of publications within the BMA literature has increased
dramatically in the past decade, reflecting the growing interest
in this topic; however, the number of unique terms is growing
even more quickly (Figure 1). Thus, since the 1990s, there
has been an increasing diversity and lack of consensus for
nomenclature relating to BMA research. Indeed, new terms
continue to be proposed to this day (74). It is likely that research
into BMAwill continue expanding, and therefore it is essential to
adopt a standardised nomenclature to provide a foundation and
consensus for this growing field.
Secondly, reviewing the history of BMA research has
identified key concepts and methods relevant to studies of
BMA (Table 1). A standardised nomenclature must therefore
incorporate terms, abbreviations and units related to these
concepts and methods.
The following sections provide further discussion of
the nomenclature for each of these, concluding with
recommendations for the terms, abbreviations and units to
be used in future reports of BMA research.
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TABLE 3 | Summary of terms and abbreviations used to refer to bone marrow adipocytes.
Term Abbreviation Year first used* No. of papers using this term* Recommended term(s) and abbreviation(s)
BONE MARROW ADIPOCYTE
Adipocyte – 1981 39 Bone marrow adipocyte (BM adipocyte, BMAd)
AC 2018 1
Adipose cell – 1971 16
Adip 2005 1
Bone adipocyte – 1981 6
Marrow adipocyte – 1978 105
Marrow adipose cell – 1971 8
Bone marrow adipocyte – 1976 100
BM adipocyte 1995 30
BMA 2016 17
BMAd 2019 2
MAT adipocyte 2015 6
BMAT adipocyte 2018 3
BM-A 2013 2
BM-AD 2018 2
Marrow AC 2016 1
Bone marrow adipose cell – 1974 3
Marrow-associated adipose cell – 1974 1
Medullary adipocyte – 2010 1
Skeletal adipocyte – 2015 1
Yellow adipocyte – 2019 1
BONE MARROW FAT CELL
Fat cell – 1893 48 Don’t use
FC 1935 1
Fatty cell – 1985 3
Marrow fat cell – 1931 14
Bone marrow fat cell – 1966 10
BM fat cell 1998 1
Fat-containing cell – 1980 2
FCC 1983 1
OTHER TERMS (SEE SUPPLEMENTARY TABLE 2)
Data are presented as described for Table 2; asterisks (*) are shown in the column headers to emphasise that other uses may exist.
Based on this and other considerations (described in the main text), we recommend use of the term bone marrow adipocyte, abbreviated as BM adipocyte or BMAd. Terms related to
measurements of bone marrow adipocytes, such as “adipocyte density,” have not been included and are shown instead in Tables 6–8. Additional terms and abbreviations, as well as
references for papers using each combination, are provided in Supplementary Table 2.
NOMENCLATURE RECOMMENDATIONS
Bone Marrow Adiposity
We define bone marrow adiposity as “The phenomenon of fat
storage within the BM, primarily within BM adipocytes.” This
can be considered an overarching concept for the field: it is the
central theme that links several diverse disciplines, including
haematology, bone biology, metabolism, endocrinology, stem
cells, developmental biology, oncology, gerontology, and beyond.
Given the centrality of this concept, we think it is important to
provide both a clear definition and a standardised abbreviation
for use in future studies. The abbreviation “BM adiposity”
is recommended because “BM” is already used across the
biomedical literature to refer to bone marrow, and therefore
“BM adiposity” should be widely understandable. However,
we also recommend the abbreviation “BMA” for two reasons:
firstly, this abbreviation for “bone marrow adiposity” has become
increasingly common in the literature since its first use in 2013
(Table 2); and, secondly, “BMA” is now recognised for this
meaning through its use in the name BMAS (the International
Bone Marrow Adiposity Society) and in the names of the
five international meetings devoted to this topic (BMA2015–
BMA2019) (4, 75, 76). It is important to note that BMA has also
been used as an acronym for “bone marrow aspiration” (77) and
“bone marrow aspirate” (78); however, the increasing use and
recognition of BMA to refer to bone marrow adiposity should
minimise any confusion with these other uses.
In considering the concept of BMA, it is essential to also
highlight the terms “yellow marrow,” “fatty marrow,” and
“red marrow.” Each of these refers to concepts intimately
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TABLE 4 | Summary of terms and abbreviations used to refer to bone marrow adipose tissue, yellow adipose tissue, or marrow fat.
Term Abbreviation Year first used* No. of papers using this term* Recommended term(s) and abbreviation(s)
BONE MARROW ADIPOSE TISSUE
Adipose tissue – 1883 17 Bone marrow adipose tissue (BMAT)
Adipose tissue from bone marrow – 1999 1
Adipose marrow – 1991 4
Adipose marrow tissue – 2017 1
Marrow adipose – 1971 2
Marrow adipose tissue – 1971 31
MAT 2012 56
Marrow-associated adipose tissue – 1974 1
Bone marrow adipose – 1979 5
bone marrow adipose tissue – 1974 34
BMAT 2007 49
BM adipose tissue 1988 6
MAT 2014 15
BM-AT 2019 1
MARROW FAT
Marrow fat – 1954 101 Marrow fat or Bone marrow fat (BM fat)
MF 2008 3
Bone marrow fat – 1936 80
BM fat 2002 3
BMF 2007 11
MF 2014 1
Medullary fat – 1994 2
Bone fat – 2010 1
YELLOW ADIPOSE TISSUE
Yellow adipose tissue – 1883 2 Don’t use
YAT 2011 4
Yellow adipose – 2016 1
Yellow fat – 1933 2
Yellow adipose marrow – 2018 1
Fatty tissue – 1922 1
Fatty yellow adipose tissue – 2019 1
Bone marrow fatty tissue – 1993 1
Data are presented as described for Table 2; asterisks (*) are shown in the column headers to emphasise that other uses may exist. Based on this and other considerations (described
in the main text), we recommend use of the term bone marrow adipose tissue, abbreviated as BMAT. Use of “marrow fat” or “bone marrow fat (BM fat)” is also acceptable, given the
long-standing use of these terms in the BMA literature. References for papers using each combination of term and abbreviation are provided in Supplementary Table 3.
related to BMA and has longstanding and widespread use
in the field (Table 2). Thus, “yellow marrow” and “fatty
marrow” are used to refer to more-lipid-laden regions of
BM whereas “red marrow” refers to those regions of the
BM where adiposity is less prominent and haematopoiesis
predominates; each of these terms is also used for macroscopic
descriptions of different regions of BM, often in clinical
contexts. Although numerous variations of these three
terms have been used, “yellow marrow,” “fatty marrow,”
and “red marrow” are by far the most common (Table 2 and
Supplementary Table 1). Thus, given their widespread use,
historical significance and clinical recognition, we recommend
continued use of these terms in future studies relevant
to BMA.
Further details of these four recommended terms, and the
many terms that we recommend to avoid using, are provided in
Table 2 and Supplementary Table 1.
Bone Marrow Adipocytes
A defining feature of BMA is the storage of lipid within
bone marrow adipocytes. We define these cells as a population
of bona fide adipocytes, that is, a cell type whose main
functional and morphological characteristic is the storage and
metabolism of lipids in a single large or several smaller
triglyceride-filled vacuoles. This distinguishes adipocytes from
other cell types, such as hepatocytes and myofibers, that in
principle are also able to store triglycerides ectopically. In these
latter cells, lipid accumulation is thought of as predominantly
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TABLE 5 | Summary of terms and abbreviations used to refer to different subtypes of BMAT and BMAds.
Term used Abbreviation Year first used* No. of papers using this term* Recommended term(s) and
abbreviation(s)
CONSTITUTIVE OR REGULATED BMAT AND BMAds
Constitutive marrow adipose tissue cMAT 2014 26 Use of cBMAT, cBMAd, rBMAT, and
rBMAd is acceptable (But when
discussing subtypes, it is preferable to refer
to skeletal location of the BMAT and
BMAds)
Constitutive MAT 2017 1
Constitutive bone marrow adipose tissue cBMAT 2017 7
Constitutive BMAT 2017 2
Constitutive bone marrow adipocyte cMAT adipocyte 2015 6
cBMA 2016 7
Regulated marrow adipose tissue rMAT adipocyte 2014 26
Regulated MAT 2017 1
Regulated bone marrow adipose tissue rBMAT 2017 7
Regulated BMAT 2017 2
Regulated bone marrow adipocyte rMAT adipocyte 2015 6
rBMA 2016 8
– 2017 1
DISTAL OR PROXIMAL BMAT AND BMAds
Distal marrow adipose tissue distal MAT 2016 1 Use “distal” or “proximal” to refer to
BMAT/BMAd location within long
bones
Distal marrow fat – 1979 1
Distal tibia marrow adipose tissue dMAT 2017 1
Proximal marrow adipose tissue Proximal MAT 2016 1
Proximal marrow fat – 1979 1
Proximal tibia marrow adipose tissue pMAT 2017 1
BONE-SPECIFIC TERMS
Femoral adipose cell – 1977 1 When required, use bone-specific
terms to indicate location of BMAT or
BMAds (see text for further details)
Femur marrow fat FMF 1984 1
Tibial adipose bone marrow – 1985 1
Vertebrae adipose cell – 1977 1
Vertebral fat – 1989 1
Intravertebral bone marrow fat – 2002 1
Vertebral bone marrow fat – 2012 1
VMB fat 2017 1
Vertebral BMAT vBMAT 2018 1
Vertebral marrow fat – 2012 1
Vertebral MAT vMAT 2018 1
BMAT WITHIN RED OR YELLOW MARROW
Red marrow fat – 1940 2 Don’t use
Red bone marrow fat – 2001 2
RBM fat 2019 1
Red marrow adipose tissue rMAT 2018 2
Yellow marrow adipose tissue yMAT 2018 2
Data are presented as described for Table 2; asterisks (*) are shown in the column headers to emphasise that other uses may exist. When necessary, we recommend indicating
site-specific differences in BMAT/BMAd subtypes by referring to the skeletal site (e.g., “femoral,” “tibial,” “vertebral”) and the location within these bones (e.g., “proximal” or “distal”).
Use of “constitutive” or “regulated” is also acceptable, with the recommended acronyms being cBMAT, cBMAd, rBMAT, and rBMAd, consistent with the recommended nomenclature
for bone marrow adipocytes (BMAd) and bone marrow adipose tissue (BMAT). Further considerations are provided in the main text. References for papers using each combination of
term and abbreviation are provided in Supplementary Table 4.
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TABLE 6 | Summary of terms and abbreviations used to refer to progenitors for BMAds.
Abbreviation Term used Year first used* No. of papers using this term* Recommended term(s) and
abbreviation(s)
SSC Skeletal stem cell (SSC) 2004 12 Skeletal stem cell (SSC)
Skeletal stem cell (no abbreviation) 2004 11
Mouse skeletal stem cell (mSSC) 2015 1
human skeletal stem cell (hSSC) 2018 1
BMSC Bone marrow stromal cell 2004 20 Use BMSC to refer to bone marrow
stromal cells (see text for further
considerations)
Bone marrow mesenchymal stem cell 2013 5
Bone marrow mesenchymal stem cell 2012 1
Bone marrow stromal cell (mBMSC)** 2015 1
Bone mesenchymal stem cell 2016 1
Bone-derived marrow mesenchymal stem cell 2017 1
Bone marrow stromal cell (BM stromal cell) 2017 1
Bone marrow mesenchymal cell 2018 1
Bone marrow mesenchymal stromal cell 2018 1
Not defined 2018 1
Bone marrow mesenchymal stem/stromal cell 2019 1
MSC Mesenchymal stem cell 2003 59 Don’t use
Mesenchymal stromal cell 2012 10
Abbreviation not defined 2015 5
Human mesenchymal stem cell (hMSC) 2004 4
Bone marrow mesenchymal stromal cell 2014 4
Mesenchymal stem/stromal cell 2016 4
Marrow stromal cell 2003 3
Bone marrow mesenchymal stem cell 2015 3
Bone marrow stromal cell 2004 2
Human bone marrow stromal cell (hMSC) 2004 1
Bone marrow mesenchymal stem cell 2012 1
Mesenchymal progenitor 2016 1
Bone marrow-derived mesenchymal stem cell 2018 1
Bone mesenchymal stem cell 2018 1
BM-MSC Bone marrow mesenchymal stem cell 2013 5 Don’t use
Bone marrow mesenchymal stromal cell 2018 2
Bone marrow MSC 2017 1
Bone marrow skeletal stem cell‡ 2018 1
Bone marrow stromal stem cell‡ 2019 1
No abbreviation used (see Supplementary Table 5)
Data are presented as described for Table 2; asterisks (*) are shown in the column headers to emphasise that other uses may exist. Terms are organised by abbreviation used, and
then by frequency and date of use. Further considerations are provided in the main text. Terms used without an abbreviation, and references for papers using each combination of term
and abbreviation, are presented in Supplementary Table 5.
**mBMSC, mouse bone marrow stromal cell.
‡Although we recommend using “skeletal stem cell” and “bone marrow stromal cell,” the former should be abbreviated as “SSC” rather than “BM-MSC”; and the latter should be
described as a “stromal cell,” not a “stem cell,” and should be abbreviated as “BMSC,” not as “BM-MSC”.
pathological, presumably due to lipotoxic reactions. In addition,
haematopoietic stem cells and osteoblasts are also capable of
lipid uptake (1–3). However, unlike these other cell types, mature
adipocytes are uniquely equipped for metabolising and storing
triglycerides and intermediates of lipid metabolism and feature a
higher level of resistance to lipotoxicity. We would therefore also
recommend against use of less-specific or even colloquial terms,
including “fatty cell” or “fat cell” in a combination with the bone
marrow, as these may refer to any type of lipid-containing cell
(Table 3 and Supplementary Table 2).
A number of abbreviations to specifically define bonemarrow-
resident adipocytes have been used in the recent literature
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TABLE 7 | Summary of terms, abbreviations, and units that have been used to report histomorphometric measurements of bone marrow adiposity.
Measurement type Year first reported* No. of papers* Recommended term(s) Recommended abbreviation(s)
and unit(s)
Adipocyte area (per
cell; mean or median)
2002 28 Adipocyte area
(mean or median)
Ad.Ar, µm2 (Showing the frequency
distribution of Ad.Ar is recommended)
Adipocyte area (total) 2015 1 Don’t use (instead report as % Ma.Ar or % T.Ar)
Adipocyte diameter
(per cell; mean or
median)
1989 25 Adipocyte diameter
(mean or median)
Ad.Dm, µm (Showing the frequency
distribution of Ad.Dm is
recommended)
Adipocyte perimeter
(per cell; mean or
median)
2002 5 Adipocyte perimeter
(mean or median)
Ad.Pm, µm (Showing the frequency
distribution of Ad.Pm is
recommended)
Adipocyte perimeter
(total; mean or median)
2015 1 Don’t use (instead report average Ad.Pm per cell, as above)
Adipocyte density
(cells per field, area, or
volume)
1990 70 Adipocyte density or
Adipocyte number
N.Ad/Ma.Ar, N.Ad/Ma.V, N.Ad /T.Ar,
N.Ad /TV. Units should be clearly
stated (e.g., cells/mm2, cells/µm2,
etc …)
Adipocyte number
(absolute N.Ad without
clearly defined referent)
1993 10 Don’t use (instead report Adipocyte density or Adipocyte number as N.Ad per referent area or
volume, as above)
Adipose area (per
field, marrow area or
tissue area)
1950 39 Adipose area or Adipose
tissue area
Report as adipose area (Ad.Ar)
relative to marrow area (Ma.Ar) or
tissue area (T.Ar). This must be
presented as %
Adipose tissue area
(absolute)
2017 1 Don’t use (instead report as % Ma.Ar or % T.Ar, as above)
Adipose volume (per
field, marrow volume or
tissue volume)
1991 29 Adipose volume or
Adipose tissue volume
Report as adipose volume (Ad.V)
relative to marrow volume (MA.V)
or tissue volume (TV). This must be
presented as %.
Adipose volume
(absolute)
1983 1 Don’t use (instead report as % Ma.V or % TV, as above)
Other Measurements (Supplementary Table 6) Don’t use
Terms are grouped based on the type of measurement reported. For each type of measurement, several different terms, abbreviations and units have been used in the literature; these
variants are shown in Supplementary Table 6. For the Year first reported and the Number of papers, asterisks (*) are shown to emphasise that other uses may exist. We recommend
that measurements of BMAd density are presented as cell number relative to the area or volume of the marrow or total tissue, and that these are reported as “Adipocyte density”;
however for consistency with the published guidelines for bone histomorphometry (5), it is also acceptable to describe this measurement as “Adipocyte number,” provided that a suitable
referent region is used. Adipocyte area (Ad.Ar; µm2 ) or volume (Ad.V; µm3) can be reported either for individual adipocytes or for the sum of all adipocytes within the regions analysed.
The former should be reported as the mean or median per adipocyte or as a distribution of adipocyte areas or volumes per sample. The latter should be reported as “Adipose area”
and presented as % relative to the area or volume of the marrow (Ma) or total tissue (T). This is consistent with the standardised nomenclature for bone histomorphometry (5), and
with our recommendations for BMA measurements based on MRI/MRS or CT (Tables 8, 9). In some instances, it may be necessary to use “Extravascular marrow” area or volume
(ExVa.Ma.Ar or ExVa.Ma.V). This and further considerations are discussed in the main text. References for papers using each combination of term, abbreviation and unit are provided
in Supplementary Table 6.
on BMA. Our recommendation is to maintain consistency
with the broader context of adipocyte biology and bone
histomorphometry, where adipocytes are commonly abbreviated
with “Ad” (5). We therefore propose the consistent use of the
terms “BMAd” or “BM adipocyte” to designate mature adipocytes
within the bone marrow (Table 3 and Supplementary Table 2).
In addition to their ability to store lipids, another important
property of BMAds is secretion of bioactive factors. This is
reminiscent of both white and brown adipocytes, which release
hormones, lipid species, cytokines, and other factors to exert local
and systemic effects (79). Collectively, such adipocyte-derived
secreted factors are known as “adipokines” and these contribute
extensively to the physiological and pathological functions of
adipose tissue (79). BMAds are also becoming increasingly
recognised for their ability to secrete adipokines and thereby
exert paracrine and endocrine functions (80). The two most
prominent adipokines are the hormones leptin and adiponectin,
which regulate energy homeostasis and have other diverse effects
(79). BMAds express and secrete leptin both in primary culture
and after in vitro differentiation from human bone marrow
stromal cells (BMSCs) (81–83). BMAds also express and secrete
adiponectin and might influence circulating concentrations of
this adipokine (80, 84, 85). This suggests that BMAds might have
endocrine functions.
BMAds also secrete many other endocrine and paracrine
factors, including RANKL (86–88), DPP-4 (89), and stem cell
factor (SCF) (90); cytokines such as interleukin-6 (IL-6), IL-3, IL-
8, tumor necrosis factor-α (TNF-α), CXCL1, CXCL2, CXCL12,
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TABLE 8 | Summary of the most common terms, abbreviations, and units that have been used to report MRI/1H-MRS-based measurements of bone marrow adiposity.
Term Abbreviations used Units used Year first used* No. of papers
using this term*
Recommendations for
MRI/MRS measurements
FAT FRACTION
Fat fraction None; FF n.s.; %; Lipid/water ratio 1999 27 Fat fraction (FF), Bone
marrow fat fraction (BMFF),
proton density fat fraction
(PDFF). Values should be
reported as %.
Marrow fat fraction None; FF; MFF n.s.; %; Lipid/water ratio 1992 27
Bone marrow fat fraction None; BM fat fraction; BMF;
BMFF; FF
n.s.; %; Lipid/water ratio 1995 23
Proton density fat
fraction
None; proton density FF; PDFF;
bone marrow PDFF
n.s.; % 2014 21
Signal fat fraction; fat signal
fraction
None; sFF n.s.; % 2012 7
Lipid fraction; bone marrow
lipid fraction
None; LF %; Lipid/water ratio 1985 4
FAT CONTENT
Fat content None; FC n.s.; % 1987 15 Don’t use for reporting
MR-based measurements of
fat fraction.
Bone marrow fat content None; BMF content; bone
marrow FC; FC
n.s.; %; Lipid/water ratio 2009 11
Marrow fat content None %; % Fat fraction; L 2005 9
Bone marrow adipose
tissue content
MAT content; BMAT content n.s.; %; Lipid/water ratio 2016 3
RATIO (FAT/WATER OR LIPID/WATER)
Lipid/water ratio None; l/w; LWR %; Lipid/water ratio 2004 13 Don’t use
Fat/water ratio; bone
marrow fat/water ratio
None %; Lipid/water ratio 2014 1
Bone marrow fat/water % None % 2011 1
AREA
Bone marrow adipose
tissue area
BMA cm2 2015 1 Don’t use. Instead present
relative to marrow area
Bone marrow adiposity
cross-sectional area
CSA cm2 2017 1
Yellow bone marrow
cross-sectional area
CSA mm2 2013 1
OTHER TERMS (SEE SUPPLEMENTARY TABLE 7)
Terms are grouped into subcategories (bold, capitalised text) based on the wording used. Other data are presented as described for Tables 2–7; for the Year first reported and the
Number of papers, asterisks (*) are shown to emphasise that other uses may exist. We recommend that MRI/MRS-based readouts be reported as fat fraction, because this is the
approach used most commonly in the existing literature. For consistency, fat fraction measurements should be reported as %, rather than as lipid/water ratios. Measurements of BMAT
area (Ad.Ar) should be reported as % of marrow area (M.Ar), i.e., Ad.Ar/M.Ar, as recommended for histological or CT-based measurements (Tables 7, 9). Further considerations are
discussed in the main text. Additional terms/abbreviations/units, as well as references for papers using each combination, are provided in Supplementary Table 7.
andMCP-1 (91–95); lipid species, such as free fatty acids (96–98);
and RNA molecules within extracellular vesicles (80). Through
these factors BMAds are reported to modulate haematopoiesis
and skeletal remodelling. A full discussion of these functions is
beyond the scope of this position paper, but more details are
available in several recent reviews (80, 99, 100).
Relating to lipid storage, an unresolved question concerns BM
adipocytes’ unilocular vs. multilocular nature. These properties
are traditionally linked to white and brown adipocyte identity,
respectively (79, 101). Some studies suggest that BMAds with
a brown adipocyte-like phenotype can occur in the bone
marrow cavity (102), and brown adipocyte-like phenotypes
can be induced in vitro using cell culture models of BMAds,
for example after overexpression of FoxC2 (103) or SIRT1
(103). However, recent data indicate that in vitro cell models
do not reliably recapitulate the properties of BMAds in vivo
(74). Indeed, microarrays show that UCP1 transcripts are not
enriched in whole BM of mice or humans (104, 105), nor
is Ucp1 expression greater in BMAds vs. white adipocytes of
mice (106). Recent work using lineage tracing and genetic
models has also demonstrated that BMAds do not express Ucp1
during development or after adrenergic stimulation in mice
(107). Similarly, primary BMAd progenitors have very limited,
if any, brown adipogenic potential (89), and BMAds in vivo
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TABLE 9 | Summary of terms, abbreviations, and units that have been used to report CT-based measurements of bone marrow adiposity.
Imaging method Measurement type Year first
reported*
No. of papers* Recommended
term(s)
Recommended
abbreviation and unit
SECT, DECT or µCT
(Without contrast agent)
Fat fraction (% or fraction) 1987 8 Fat fraction; Bone
marrow fat fraction
FF (%), BMFF (%)
Adipose volume (per marrow
volume)
2019 2 Adipose volume Ad.V/Ma.V (%)
BM density 1986 6 Don’t use (Report as Adipose volume, FF or BMFF, as above)
Adipose volume (per tissue
volume)
2011 2 Don’t use (Report as % Ma.V, as above)
µCT (Samples stained with
osmium tetroxide or other
contrast agents)
Adipose volume (per marrow
volume)
2012 11 Adipose volume Ad.V/Ma.V (%)
Adipocyte density (per marrow
volume)
2014 2 Adipocyte density or
Adipocyte number
N.Ad/Ma.V (Cell
number/unit volume)
Adipocyte area (Distribution of
individual adipocyte areas)
2015 1 Adipocyte area
(mean or median)
Ad.Ar, µm2 (Show
frequency
distribution)m
Total adipocyte area (per Slice) na na Adipose area Ad.Ar/Ma.Ar (%)
Adipocyte volume (per slice) na na Adipocyte volume
(mean or median)
Ad.V, µm3 (show
frequency distribution)
Adipose volume (per tissue or
total volume)
2014 12 Don’t use (Report as % Ma.V, as above)
Adipose volume (Unclear if per
tissue volume or per marrow
volume)
2015 4
Adipose volume (absolute) 2015 10
Data are presented as described for Table 7, except that imaging method is also indicated. For the Year first reported and the Number of papers, asterisks (*) are shown to
emphasise that other uses may exist. For each type of measurement, several different terms, abbreviations, and units have been used in the literature; these variants are presented in
Supplementary Table 8. Most in vivo studies using SECT or DECT report measurements of fat fraction or relative adipose volume, and therefore we recommend reporting these as
indicated in the table. Most ex vivo µCT studies assess adipose volume normalised to marrow volume or total tissue volume, although in some cases it is unclear which of these is used
for normalisation. Other studies present absolute adipose volume or assess adipocyte density or area. We recommend that µCT-based readouts of adipose volume or area be reported
relative to marrow volume (Ma.V) or marrow area (Ma.Ar), and that individual adipocyte areas be reported as the mean or median, or as a frequency distribution. This is consistent
with our recommendations for histology-based measurements (Table 7). Further considerations are discussed in the main text. References for papers using each combination of term,
abbreviation and unit are provided in Supplementary Table 8.
do not undergo cold-induced glucose uptake (108). However,
multilocular BMAds do exist and account for around 5% of
all BMAds in the long bones of mice (107). Thus, while it
seems that BM adipocytes are distinct from brown adipocytes,
it is unlikely that this multilocularity is indeed equated to
brown adipocyte-like functions of BMAds. This also pertains to
BMAd-intrinsic ability for rapid lipid mobilization in response
to adrenergic stimulation or other physiological stimuli known
to recruit brown adipocytes for their main function, which is
thermogenesis. These remain open issues to be assessed in greater
detail. Future authors may therefore opt to add further attributes
to the term “bone marrow adipocyte” to better define parameters
such as number of vacuoles (locularity), and also to reference
anatomical localisation or metabolic characteristics. This relates
to the recent discussion on distinct types of BMAds, regulated
and constitutive, which will be discussed in the section on
Subtypes of Bone Marrow Adipocytes.
Bone Marrow Adipose Tissue
One area of debate is whether BMAds are simply a subpopulation
of BM cells that constitute a part of BM as a tissue, or
whether, collectively, BMAds act as an integrated adipose tissue.
References to “adipose tissue” within the BM can be found
as early as 1883 (10), and studies from the 1940s and 1950s
also proposed “yellow marrow” or “marrow fat” to be an
adipose tissue, based on its similar lipid composition with
WAT depots (23, 24). In 1967, Zakaria and Shafrir studied
explants of “yellow bone marrow” (YBM), concluding: “The
experiments demonstrate the capacity of YBM to synthesize
fatty acids and glycerol from glucose, to take up and esterify
long-chain FFA (free fatty acids) from an external medium
and to release FFA under hormonal stimulation. All these
activities are typical of adipose tissue function. Thus, the YBM
seems to represent a metabolically active variety of fat store,
similar to depots in other anatomical sites, but presumably
with a specialized local importance” (31). These studies support
the concept that BMAds, collectively, form an integrated
adipose tissue.
One caveat, discussed further in the section on Subtypes of
Bone Marrow Adipocytes, is that BMAd characteristics vary
depending on skeletal site. The studies described above focussed
on the yellow marrow, in which BMAds form a contiguous unit
that is morphologically similar to white adipose tissue (109).
However, BMAds also exist interspersed among the red marrow,
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where they do not form a spatially contiguous grouping; it is less
clear whether these cells, designated “regulated” BMAds, can be
considered as an adipose tissue.
This issue was debated extensively among the members of the
Nomenclature WG. After much discussion, we concluded that
it is appropriate to refer to BMAds as an adipose tissue, even
for those adipocytes interspersed among the red marrow. This
decision is based on two key points. Firstly, even in white adipose
tissue, adipocytes comprise <25% of the total cell population
(110). Thus, the fact that BMAds do not predominate in the
red marrow does not preclude these from being considered as
an adipose tissue. Secondly, “tissue” has been defined as “an
aggregation of similarly specialized cells united in the performance
of a particular function” (5); hence, possessing a common
function is more important than the physical grouping of the
cells. Although the roles of BMAds are still being elucidated, it is
clear that these cells work together to perform common functions
(109), and therefore they can be considered as an integrated
adipose tissue.
A second point of debate regards how to abbreviate “bone
marrow adipose tissue.” By far the most common abbreviations
for this are “MAT” and “BMAT” (Table 4). One benefit of
“MAT” is that this is more consistent with other abbreviations
in the adipose field, such as “WAT” and “BAT.” One downside
to “BMAT” is that this also been used to refer to a “bone
marrow aspirate and trephine” biopsy (111); however, there
are several benefits to the use of “BMAT” to abbreviate
“bone marrow adipose tissue.” Firstly, by using “BM,” “BMAT”
refers unambiguously to the BM and is consistent with other
abbreviations recommended in this standardised nomenclature
(e.g., BMA, BMAd, BMSC, BMFF). Secondly, in the BMA
literature the use of “BMAT” precedes use of “MAT” by 5
years, and therefore there is a historical priority for “BMAT”
(Table 4). Finally, use of “BMAT” has been recommended in
a previous editorial (112), which provides further rationale for
its continued use. In summary, we recommend the term “bone
marrow adipose tissue” and the abbreviation “BMAT.” This can
be defined as a collection of BMAds, which may be clustered
together or interspersed among the haematopoietic marrow, that
work together to perform common functions.
Two other terms are also recommended. Despite the
longstanding references to adipose tissue within the BM, it has
historically been more common to refer to “marrow fat” or
“bone marrow fat” (Table 4). These terms continue to be used
to this day, often in clinical reports and/or to reflect gross
measurements of BMA (Supplementary Table 3). Considering
the historical prominence and continued use of these terms, we
have included “marrow fat” and “bone marrow fat (BM fat)” in
the standardised BMA nomenclature. However, when discussing
the formation and function of BMAds as a collective, integrated
tissue, use of “bone marrow adipose tissue (BMAT)” should be
given preference.
Further details of these recommendations, and the many
terms that we recommend to avoid using, are provided in Table 4
and Supplementary Table 3.
Subtypes of Bone Marrow Adipocytes
One important concept in BMA research is that BMAds and
BMAT display distinct characteristics depending on skeletal
location. This was first shown in 1965 by Cohen and Gardiner,
who found that during starvation in rabbits, lipid is mobilised
from BMAds within the proximal red marrow but not from
BMAds in the distal yellow marrow (28). Subsequent work in the
1970s extended these observations, including the demonstration
of distinct lipid composition in proximal vs. distal BMAds
[reviewed in (113)]. This concept was relatively overlooked until
the mid 2010s, when Scheller et al. proposed the existence of
“regulated” and “constitutive” subtypes of BMAds (73, 114).
Further details, including the evidence supporting these two
subtypes, are provided in an excellent recent review (113).
Therein, regulated BMAds are “defined histologically as single
adipocytes interspersed within the haematopoietic BM. They form
gradually throughout life and accumulate with aging.” In contrast,
constitutive BMAds “form early in development, are larger in size,
and appear histologically as densely packed groups of adipocytes
with little intervening haematopoiesis” (113).
The terms regulated and “constitutive” have since gained
traction in the field, as evident through the increasing use of the
abbreviations “rMAT” or “rBMAT” and “cMAT” or “cBMAT”
to refer to these subtypes (Table 5). However, this classification
raises an important question: are there only two general classes,
or is the heterogeneity less binary than this? For example, in the
mouse tibia, proximal (“regulated”), and distal (“constitutive”)
BMAds display different properties, in particular in terms of
fatty acid saturation, but, like their “regulated” counterparts, the
“constitutive” BMAds can also be altered in certain contexts
(115, 116). Moreover, in some models of lipodystrophy there is
a loss of cBMAT at the distal tibia, whereas cBMAT in caudal
vertebrae is maintained (117). Thus, like rBMAT, cBMAT can
also display plasticity in response to environmental cues, and
cBMAT properties vary depending on skeletal site. Finally, most
studies of cBMAT and rBMAT are based in animalmodels; hence,
it remains unclear to what extent these exist as distinct subtypes
in humans.
Because of these complexities, as a priority we recommend
referring to BMAT and BMAd subtypes based on their
anatomical location, in preference to using the “constitutive”
and “regulated” terminology. This approach, which already
is common in the literature (Table 5), provides a definitive,
unambiguous description that addresses the issue of site-
specific characteristics. However, given the increasing use of
“constitutive” and “regulated,” and the evidence supporting
existence of these two broad subtypes (113), we accept that there
is still value in continued use of these terms. Therefore, if authors
do wish to use these terms, we recommend using rBMAT and
cBMAT to refer to the regulated and constitutive subtypes of
BMAT, and rBMAd and cBMAd when referring to these subtypes
of BM adipocytes.
Further details of these recommendations, and the many
terms that we recommend to avoid using, are provided in Table 5
and Supplementary Table 4.
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Progenitors for Bone Marrow Adipocytes
BMAds originate frommarrow-derived skeletal stem cells (SSCs)
(72, 118). These cells go by different names, based on two
different concepts regarding their differentiation properties and
their tissue of origin. The first concept emanates from in vivo
transplantation studies. These studies confirm the existence of
multipotent progenitors present in BM stroma that can generate
heterotopic bone/marrow organs (ossicles) with donor-derived
skeletal cell phenotypes (chondrocytes, osteoblasts, stromal cells),
including BMAds [reviewed in (119)]. The term Bone Marrow
Stromal Cell (BMSC) is a time-honoured term used to indicate
the population of non-hematopoietic, non-endothelial, rapidly
adherent cells isolated from BM; adherence in culture is one
characteristic property of these stromal cells. Clonal analysis
of BMSCs coupled with in vivo transplantation revealed the
presence of a subset of multipotent cells (120, 121). Later, these
multipotent cells were found to be sinusoidal pericytes, cells
that wrap around blood vessels providing them with stability.
Furthermore, they were found to restore the perivascular
compartment from which they originate (the ability to self-
renew), making these cells bona fide SSCs (122). Thus, SSCs
are a multipotent, self-renewing subset of BMSCs: all SSCs are
BMSCs, but not all BMSCs are SSCs. It is essential to emphasise
this because these terms have been used inconsistently in the
literature, causing confusion about the relationship between SSCs
and BMSCs.
Notably, the term “skeletal stem cell” currently describes a
biological activity rather than a well-defined cell phenotype,
since the specific identity of multipotent and self-renewing
SSCs is not yet clear. As discussed in the accompanying BMAS
Methodologies position paper by Tratwal et al., agreement
on how to purify SSCs has not yet been reached: even
populations highly enriched by using certain cell surface markers
are still not homogeneous. Nonetheless, the use of the term
“SSC” is appropriate based on the retrospective evidence of
stemness demonstrated by the generation of ossicles by clonal
populations of BMSCs. However, it is important to note that
other populations of SSCs have recently been identified in the
growth plate and in the periosteum in both mice and humans,
but it does not appear that SSCs from these origins contribute to
BMA [reviewed in (123)] (104, 123–126). Similarly, stromal cells
capable of adipogenesis ex vivo have been isolated from cortical
bone of the femoral diaphysis and cancellous/cortical bone of
the proximal epiphysis of rats (127, 128). Although it remains to
be confirmed if these cells can generate BMAds in vivo, their ex
vivo adipogenic capacity differs depending on skeletal site. This
echoes the site-specific differences in BMAd subtypes discussed
in the previous section. Thus, the tissue origin of SSCs must
always be identified. Indeed, not all populations of SSCs give rise
to adipocytes, as determined by in vivo transplantation or lineage
tracing in mice. Of note, “in vivo” is the operative term here, as
it is known that the in vitro assay for adipogenesis is prone to
artefact. In many fibroblastic populations, a few cells accumulate
fat from serum in themedium, but do not synthesize triglycerides
or hydrolyse them to the same extent as bona fide adipocytes.
According to the second concept, the term “Mesenchymal
Stem Cell (MSC)” was introduced, based on the ability of
BMSCs/SSCs to make cells and tissues of mesodermal origin.
These include not only skeletal cell types (chondrocytes,
osteoblasts and BMAds) but also non-skeletal phenotypes such
as myoblasts, tenocytes, fibrocytes (ligament), white adipocytes,
and others (124). However, as defined by developmental
biologists, mesenchyme is an embryonic connective tissue that
makes connective tissue, blood, and blood vessels during foetal
development, and is not found in post-natal tissue (129). In
spite of this, it was proposed that “MSCs” reside in all post-
natal tissues, based on non-specific cell surface markers shared
by virtually all fibroblastic cells (130), and that all “MSCs” are
pericytes (125), able to give rise to osteoblasts, chondrocytes
and adipocytes, making them equivalent to SSCs within the
BM. However, during embryonic development, none of the
non-skeletal cell types, including pericytes, have a common
embryonic origin (118). Lastly, the “MSC” term emerged from
less-than-rigorous in vitro studies; more-recent in vivo work has
confirmed that the progenitor activity of different populations of
perivascular stromal cells (if any) is always restricted to that of
the tissue of origin (126).
For these reasons, the use of the term “Mesenchymal
Stem Cell” and any other definition including the word
“Mesenchymal,” especially the use of the acronym “BMSC” to
indicate bone marrow mesenchymal stem cells rather than bone
marrow stromal cells, is not scientifically accurate and is not
recommended. Thus, we recommend using “SSCs” to refer to
“Skeletal Stem Cells” and “BMSCs” to refer to “Bone Marrow
Stromal Cells.” Describing the anatomical location from which
these cells are isolated, as well as the species of origin, is also
important when reporting studies of SSCs and BMSCs.
Further details of these recommendations, and the terms and
abbreviations that we recommend to avoid using, are provided in
Table 6 and Supplementary Table 5.
BMAT Morphometric Analyses
The elaboration of an appropriate nomenclature for BMAT
morphometry cannot be conceived without considering the
guidelines for bone histomorphometry that have been established
for more than 25 years (5, 131). Indeed, many of the terms
usable for BMAT morphometry are well-defined and properly
abbreviated in the first Standardized Nomenclature, Symbols,
and Units for Bone Histomorphometry (131) and in its
revision (5).
As for bone, BMAT morphometry can be based on two-
or three-dimensions (2D or 3D) and applied to many types of
biological material, most commonly iliac crest bone/BM biopsies
obtained from human subjects, and bones from experimental
animals. Recent studies have also analysed BMAds within BM
plugs of transgenic mice, allowing study of BMAd development
by lineage tracing (132). A mixture of terminology for 2D and
3D techniques of analysis should not be used in the same article,
unless different methods of analysis (i.e., histology vs. micro-CT)
are used (5).
Both primary measurements and referents (i.e., some clearly
defined area or volume within the sample) must be considered.
The former include Adipocyte Area (Ad.Ar), Volume (Ad.V),
Perimeter (Ad.Pm), Diameter (Ad.Dm), and Number (N.Ad);
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each of these abbreviations is consistent with the guidelines for
bone histomorphometry (5). In addition to adipocyte number,
measurements of the size of individual adipocytes (Ad.Ar,
Ad.V, Ad.Pm, Ad.Dm) are important in the physiology and
pathology of BMAT. Indeed, changes in total BMAT may
be the result of mechanisms that lead to the increase or
decrease of either BMAd size (lipid storage/lipolytic activity)
or number (adipogenic differentiation, or BMAd apoptosis and
clearance). Size-related measurements may have meaning per
se and not require a referent. For example, they can be used
for the calculation of mean (and median) of BMAds and to
construct distribution curves; the latter provide a more accurate
representation of BMAd sizes across the sample and therefore are
the recommended method of presenting such data (Table 7).
In contrast to these measurements of BMAd size, for N.Ad,
total adipose tissue area and total adipose volume, referents are
needed, and must be properly defined. Since BM is distributed
throughout the cavities of the skeleton and includes distinct kinds
of tissues/cells (haematopoietic cells, BMAds, and BMSCs) and
is highly vascularised, the referents may be different. Some of
them (i.e., Tissue Area in 2D and Tissue Volume in 3D) have
been already defined and abbreviated (T.Ar and TV, respectively)
in the Standardized Nomenclature, Symbols, and Units for Bone
Histomorphometry (5). For studies of BMA, additional referents
to be considered include Marrow Area (Ma.Ar, in 2D) and
Marrow Volume (Ma.V, in 3D), which coincide with the spaces
of the skeleton delimited by endosteal surfaces (cancellous bone
surfaces and endocortical surfaces).
The choice between T.Ar (or TV) or Ma.Ar (or Ma.V) as
referents is important for the accurate interpretation of the
data. For example, when osteopenia does occur, the Ma.Ar (or
Ma.V) increases while T.Ar (or TV) does not. In addition, since
haematopoietic cells and adipocytes are located in the Extra-
Vascular compartment of the BM, the use of this region (Area:
ExVa.Ma.Ar, i.e., Marrow Area minus Vascular Area; Volume:
ExVa.Ma.V, i.e., Marrow Volume minus Vascular Volume) as
referent could be more appropriate and, in principle, to be
preferred in respect to Ma.Ar and Ma.V. Indeed, this Extra-
Vascular compartment can be used as a referent not only for
assessments of BMA (i.e., with total Ad.Ar, total Ad.V, or N.Ad
as the numerator), but also for measuring the percentage of
haematopoietic marrow. The latter is calculated by expressing the
haematopoietic area (Hm.Ar) or haematopoietic volume (Hm.V)
relative to ExVa.Ma.Ar or ExVa.Ma.V, respectively. As discussed
in the accompanying BMAS Methodologies paper, the ratio of
haematopoietic to adipose area (Hm.Ar./Ad.Ar.) may also be
of interest in some instances but should not be confounded
with measures of adiposity (e.g., Ad.Ar/Ma.Ar) or hematopoietic
cellularity (e.g., Hm.Ar/Ma.Ar).
One challenge is that measurement of the Extra-Vascular
Marrow compartment can be highly time-consuming. Thus,
we suggest to use the area (or volume) of the Extra-Vascular
Marrow compartment as referent in specific conditions only, for
example in mouse long bone whole-mount sections in which the
vascular spaces (sinusoids and central vein) may constitute a very
significant and dynamic area or volume (133); and, in humans,
in those haematological diseases in which BM vascularity is
known to be altered (134). Use of the Extra-Vascular Marrow
referent is, however, still limited by technological challenges,
which may resolve as whole-mount 3D microscopy and high-
resolution contrast-enhancedµCT becomemore widely available
to reconstruct, and subtract, the vascular network within the
BM space (135, 136). Subtraction of the central vein from the
Marrow Area is, however, common in whole-bone histology of
murine long bones due to the dilated lumen often associated with
retraction artefacts upon fixation (reviewed in the accompanying
BMAS Methodologies position paper by Tratwal et al.).
A final consideration, debated extensively among WG
members, is whether to use the term “Adipocyte density” or
“Adipocyte number” when describing measurements of N.Ad
relative to a referent region (i.e., Ma.Ar, Ma.V, T.Ar, TV,
ExVa.Ma.Ar, or ExVa.Ma.V). Such measurements report the
population density of BMAds within the region of interest, and
therefore we recommend that these are reported as “Adipocyte
density” (Table 7). However, one concern with the term ‘density’
is that readers may confuse this with a measurement of the
actual physical density of BMAds (i.e., mass per unit volume of
the cells); this concern was raised in the published guidelines
for bone histomorphometry (5), which therefore prioritises
the term “number” over “density” when reporting relative cell
numbers. Thus, to be consistent with these previous guidelines,
we agree that use of “Adipocyte number” is also acceptable
when describing measurements of N.Ad relative to a referent
region. What is essential is that studies should never report
measurements of N.Ad alone: a suitable referent must always
be used.
Details of the proposed nomenclature regarding BMAT
morphometry are presented in Table 7, with further information
in Supplementary Table 6.
MRI- and/or MRS-Based Analyses
MRI analysis of BMAwas first reported in themid-1980s (53–57),
but the past 20 years have seen a notable increase in publications
using MRI and/or 1H-MRS for assessment of BMA (Table 8
and Supplementary Table 7). Most studies report the fat fraction
(FF) or lipid:water ratio, calculated from the lipid and water
peaks in MR spectra (71); however, there is much inconsistency
in how these measurements are reported. As shown in Table 8,
measurements described by the term “fat fraction (FF),” or the
related terms “marrow fat fraction” or “bone marrow fat fraction
(BMFF),” typically are reported as a %, but in some cases the
actual measurement reported is the lipid/water ratio and not the
% fat fraction. Conversely, sometimes measurements described
as a “ratio” are actually reported as % fat fraction. Confusing
issues further, some studies have used the term “fat content” when
reportingmeasurements of % fat fraction, whilst others have used
this term when reporting the lipid/water ratio. In other cases,
the terms “fat fraction” or “fat content” are used, but the units
of measurement are not stated; this may cause confusion about
whether the measurement is a fraction or a ratio. Finally, MRI
has been used to report the volume or area of BMA from 3D or
2D images, respectively (Table 8).
This variability underscores the need for standardisation.
To date, most studies use the term “fat fraction,” “marrow fat
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fraction,” or “bone marrow fat fraction” to report the % fat
fraction of the BM (Table 8). These measurements typically
are based on dual-echo MRI or MRS data, which can be
subject to confounding factors (e.g., attenuation of the T2∗
signal) (71). In contrast, measurement of the proton density
fat fraction (PDFF), based on multi-echo data, removes the
effect of these confounding factors and thereby represents a
truly standardised BMA measurement (71). Thus, in addition
to 1H-MRS, PDFF is emerging as another gold-standard for
BMA quantification. Nevertheless, many studies report dual-
echo fat fraction measurements. We recommend reporting MRI
and 1H-MRS-based measurements as fat fraction (FF) or bone
marrow fat fraction (BMFF) when based on dual-echo data,
and as PDFF when based on appropriate multi-echo sequences.
These measurements should be reported as %, rather than the
lipid/water ratio.
A final issue is the ability of MR to measure the degree of
lipid saturation. Terms such as “unsaturation index” (UI) and
“unsaturated lipid fraction” (ULF) have been used (137–141),
and this capacity to assess not just BMAT quantity, but also
BMAT quality, may reveal further insights about the clinical
implications of altered BMA (71, 99). However, compared to
reports of FF, BMFF or PDFF, there are far fewer papers
reporting BMAT saturation, and therefore we feel it is too
early to recommend terms, abbreviations or units for describing
such measurements.
Further details of these recommendations, and the terms that
we recommend to avoid using, are provided in Table 8 and
Supplementary Table 7.
CT-Based Analyses
As for MRI, CT-based BMA analysis was first reported in the
mid-1980s (58, 59, 61). However, the application of these two
approaches has since diverged: MRI has found widespread use
for clinical BMA assessment in vivo but remains relatively under
used in preclinical animal studies. In contrast, only a handful
of studies have used CT to measure BMA in vivo, whereas
its preclinical use has flourished in recent years, particularly
for µCT (Table 9). The latter is primarily a result of the
development of contrast agents, such as osmium tetroxide,
that allow µCT-based visualisation and quantification of
BMA ex vivo.
Clinically, both single-energy CT (SECT) and dual-
energy CT (DECT) have been used to assess BMA in vivo
and ex vivo. SECT-based measurements of BM density,
expressed in Hounsfield Units, correlate inversely with
BMA; however, these measurements include the density
of yellow and red marrow as well as trabecular bone, and
therefore do not allow for direct quantification of BMA
(142). Nevertheless, several recent studies have used SECT
to estimate relative adipose volume within the BM based
on HU thresholds indicative of adipose tissue (108, 143).
In contrast to SECT, DECT is able to separate BMA from
the other tissue components, allowing true quantification
of BMA. Such DECT-based measurements, reported as fat
fraction (Table 9), show good agreement with MRI/MRS-based
assessment of BMA (142, 144, 145). Thus, for consistency with
nomenclature for histomorphometry and MRI/MRS-based
measurements (Tables 7, 8), we recommend that CT-based
assessment of BMA should be reported as fat fraction (FF,
%), bone marrow fat fraction (BMFF, %), or adipose volume
(Ad.V/Ma.V, %).
Ex vivo, staining of tissue samples with contrast agents allows
direct measurement of adipose volume by µCT. Most such
studies report Ad.V as the % or fraction relative to Ma.V or
TV, although a sizeable minority have reported absolute Ad.V; in
some cases, it is not clear if absolute or relative adipose volume
is being reported (Table 9). Consistent with our proposals
for BMAT histomorphometry (Table 7), we recommend that
µCT-based readouts of adipose volume should be reported
relative to Ma.V (i.e., as Ad.V/Ma.V, %). For the referent, Ma.V
should be prioritised over TV because the latter can include
bone and other tissues that necessarily exclude BMAds; the
size of these tissues may also vary based on the physiological
or pathological context, confounding analysis of BMA. Thus,
presenting Ad.V/Ma.V provides a more accurate assessment
of BMA.
An emerging application of µCT is the ability to measure the
number and size of individual BMAds. Adipocyte density (i.e.,
N.Ad/Ma.V) has been reported for samples stained with osmium
tetroxide (146) or with a Hafnium-based polyoxometalate
contrast agent (135). Similarly, nano-CT has been used to
quantify the area of individual BMAds in 2D image slices
of osmium tetroxide-stained samples, allowing the distribution
of individual BMAd areas to be determined (147). As for
BMAT histomorphometry, we recommend reporting these
readouts as “Adipocyte density” (N.Ad/Ma.V) and the frequency
distribution of “Adipocyte area” (Ad.Ar, µm2), respectively;
“Adipocyte number” may also be used in place of “Adipocyte
density,” as discussed in the section BMAT Morphometric
Analyses. An obvious extension of these methods would
be the measurement of total adipocyte area in 2D slices
of CT scans, and of individual adipocyte volume in 3D
scans. While such readouts have not yet been published
(Table 8), for the sake of foresight we recommend that
these should be reported, respectively, as “Adipose area”
(Ad.Ar/Ma.Ar, %) or frequency distributions of “Adipocyte
volume” (Ad.V, µm3).
Further details of these recommendations, and the terms that
we recommend to avoid using, are provided in Table 9 and
Supplementary Table 8.
CONCLUDING REMARKS
The study of BMA is a dynamic, vibrant, and expanding field
of research. As populations and sub-populations of cells are
more accurately defined, it may be necessary to reappraise the
nomenclature to accommodate subtle nuances found between
cells that may influence function. Similarly, it is likely that the
BMA nomenclature will have to be updated to reflect advances
in methodologies relevant to BMA research. The Nomenclature
Working Group of the International Bone Marrow Adiposity
Society will therefore endeavour to regularly reassess the field
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and make practical recommendations on nomenclature to help
define and characterise the cells and environment that initiate,
propagate and maintain BMA, and the methods used to assess
these. Such future updates will depend on the continued growth
and development of the BMA field. For now, we hope that
the nomenclature guidelines herein will provide a foundation
to support this growth; to promote collaboration; and to
provide a consensus for the diverse fields of study related
to BMA.
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